PMID- 15138331
OWN - NLM
STAT- MEDLINE
DCOM- 20040830
LR  - 20211008
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 43
IP  - 8
DP  - 2004 Aug
TI  - Versican splice variant messenger RNA expression in normal human Achilles tendon 
      and tendinopathies.
PG  - 969-72
AB  - OBJECTIVES: Versican is the principal large proteoglycan expressed in mid-tendon, 
      but its role in tendon pathology is unknown. Our objective was to define the 
      expression of versican isoform splice variant messenger ribonucleic acid (mRNA) 
      in normal Achilles tendons, in chronic painful tendinopathy and in ruptured 
      tendons. METHODS: Total RNA isolated from frozen tendon samples (normal n = 14; 
      chronic painful tendinopathy n = 10; ruptured n = 8) was assayed by relative 
      quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for total 
      versican, versican variants V0, V1, V2, V3 and type I collagen alpha1 mRNA, 
      normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Differences 
      between sample groups were tested by Wilcoxon statistics. RESULTS: Painful and 
      ruptured tendons showed a significant decrease (median 2-fold) in the expression 
      of versican mRNA, in contrast to an increased expression (median 8-fold) of type 
      I collagen alpha1 mRNA in painful tendons. Versican splice variants V0 and V1 
      mRNA were readily detected in normal samples, V3 levels were substantially lower, 
      and V2 levels were more variable. Each of V1, V2 and V3 mRNA showed significant 
      decreases in expression in painful and ruptured tendons, but V0 was not 
      significantly changed. CONCLUSIONS: Changes in versican expression relative to 
      that of collagen, and alterations in the balance of versican splice variants, may 
      contribute to changes in matrix structure and function in tendinopathies.
FAU - Corps, A N
AU  - Corps AN
AD  - Rheumatology Research Unit, Box 194, Addenbrooke's Hospital, Cambridge CB2 2QQ, 
      UK. anc@mole.bio.cam.ac.uk
FAU - Robinson, A H N
AU  - Robinson AH
FAU - Movin, T
AU  - Movin T
FAU - Costa, M L
AU  - Costa ML
FAU - Ireland, D C
AU  - Ireland DC
FAU - Hazleman, B L
AU  - Hazleman BL
FAU - Riley, G P
AU  - Riley GP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040511
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Chondroitin Sulfate Proteoglycans)
RN  - 0 (Collagen Type I)
RN  - 0 (Lectins, C-Type)
RN  - 0 (Proteoglycans)
RN  - 0 (RNA, Messenger)
RN  - 0 (VCAN protein, human)
RN  - 126968-45-4 (Versicans)
SB  - IM
MH  - Achilles Tendon/*physiology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Base Sequence
MH  - Chondroitin Sulfate Proteoglycans/*genetics
MH  - Collagen Type I/genetics
MH  - Humans
MH  - Lectins, C-Type
MH  - Middle Aged
MH  - Pain/genetics
MH  - Proteoglycans/genetics
MH  - RNA Splicing/genetics
MH  - RNA, Messenger/*analysis
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Tendinopathy/*genetics
MH  - Tendon Injuries/*genetics
MH  - Versicans
EDAT- 2004/05/13 05:00
MHDA- 2004/08/31 05:00
CRDT- 2004/05/13 05:00
PHST- 2004/05/13 05:00 [pubmed]
PHST- 2004/08/31 05:00 [medline]
PHST- 2004/05/13 05:00 [entrez]
AID - keh222 [pii]
AID - 10.1093/rheumatology/keh222 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2004 Aug;43(8):969-72. doi: 10.1093/rheumatology/keh222. 
      Epub 2004 May 11.